Over the past 5 years, AI and ML have advanced significantly in the pharmaceutical industry. We explored Generative AI, like ChatGPT, for mining drug development pipeline information. Our whitepaper documents the state-of-the-art and assesses AI’s readiness for such tasks, using Foghorn Therapeutics as a case study.
Generative AI : ChatGPT Experiments Read More »
This year saw a return to major industry events. Highlights included attending BioPharma PM, BioIT World, and BIO conferences and showcasing our Pipeline Program Management software. We launched a successful “Roadmap Informatics & Laboratory Planning Service” and completed significant client projects, including Diagnostics LIMS System, DEL Library Design & Screening, and Automated Synthesis modules.
Year in Review | Aspen Biosciences Read More »
Recently, the struggles of Enamine, a Ukrainian chemicals company, brought back some memories of growing up in war zones.
Approximately one-third of Ukrainians have evacuated, and another third are internally displaced.We stand with Ukrainians fighting for self-determination, the Russian free press, and protesters. We support aid workers managing the refugee crisis.
Making A Difference Read More »
Aspen Biosciences has continued to grow over the last quarter with the addition of 7 new team members, to help with the explosive demand for custom applications, and integrated systems in the drug discovery and diagnostics industries. These new team members bring the company size up to 70. Throughout this year, the Aspen Biosciences teams have also made meaningful improvements to existing products such as Pharm2Market and Pipeline while beginning development on Delos, a new application coming soon to the Biotechnology industry.
Aspen Biosciences: Expanding Team to Meet Industry Demand Read More »
This Thursday marked 103 years since the end of the The War to End All Wars. In a very real sense though, it also marks the beginning of a war that continues to this day. A war, that until a few years ago, I didn’t really realise we were still fighting.
Remembrance Day 2021 Read More »
San Diego Entrepreneurs Exchange (SDEE) What led up to starting Aspen Biosciences?I was working for Royal Dutch Shell (Shell) in the Netherlands when my mom and grandmother were diagnosed with pancreatic cancer. That’s when I became interested in Biotech. Searching for information about pancreatic cancer while waiting at the hospital, I realized how little we
Interview with a Member: Spotlight Read More »
Whether you’re in the lab running an experiment, taking that morning jog around the mesa as your experiment runs, or making the drive into work, there are always lots of opportunities to stay up to date with the latest news from the biotech industry. Here’s what we’ve been listening to lately: TWIV: This Week In
What’s on Our Podcast Playlist? Read More »
I recently found myself catching up on tweets, and I came across this repost by Michael Gilman, CEO of Arrakis Therapeutics, and I was reminded that over the past 20 years we’ve seen an explosive redefinition of the edges of druggable space. The nucleus of that explosion was the human genome project. In my own
Expanding Druggable Space Read More »
Pharm2Market introduces premier SAAS application for the biotech industry SAN DIEGO, CALIFORNIA, March 29, 2021 – The team at Aspen Biosciences has officially announced the launch of Pharm2Market 2.0, which offers a feature-rich upgrade from its predecessor. In December 2018, Aspen Biosciences launched Pharm2Market as a SAAS (software as a service) solution offering information on
Press Release: Aspen Biosciences Unveils Pharm2Market 2.0 Read More »
My mother’s love for books mirrored the nation’s renewed interest in Defoe’s “A Journal of the Plague Year” during the COVID-19 pandemic. This year highlighted the rapid development of mRNA therapeutics, innovative drug discovery, and our community efforts to support those affected by the crisis.
Aspen Biosciences: A Year of Innovation, Adversity, and Community Engagement Read More »
